Wang Huijuan, Wang Pingping, Wu Yu, Hou Xiukun, Peng Zechun, Yang Weiwei, Guan Lizhao, Hu Linfei, Zhi Jingtai, Gao Ming, Zheng Xiangqian
Department of Thyroid and Neck Tumor, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Department of Thyroid and Breast Surgery, Rizhao Central Hospital, Shandong, China.
PeerJ. 2020 Sep 8;8:e9675. doi: 10.7717/peerj.9675. eCollection 2020.
To explore the relationship between body mass index (BMI) and clinicopathological characteristics in patients with papillary thyroid carcinoma (PTC).
The clinical data of 1,579 patients with PTC, admitted to our hospital from May 2016 to March 2017, were retrospectively analyzed. According to the different BMI of patients, it can be divided into underweight recombination (BMI < 18.5 kg/m), normal body recombination (18.5 ≤ BMI < 24.0 kg/m), overweight recombination (24.0 ≤ BMI < 28.0 kg/m) and obesity group (BMI ≥ 28.0 kg/m). The clinicopathological characteristics of PTC in patients with different BMIs group were compared.
In our study, the risk for extrathyroidal extension (ETE), advanced T stage (T III/IV), and advanced tumor-node-metastasis stage (TNM III/IV) in the overweight group were higher, with OR (odds ratio) = 1.99(1.41-2.81), OR = 2.01(1.43-2.84), OR = 2.94(1.42-6.07), respectively, relative to the normal weight group. The risk for ETE and T III/IV stage in the obese group were higher, with OR = 1.82(1.23-2.71) and OR = 1.82(1.23-2.70), respectively, relative to the normal weight group.
BMI is associated with the invasiveness of PTC. There is a higher risk for ETE and TNM III/IV stage among patients with PTC in the overweight group and for ETE among patients with PTC in the obese group.
探讨甲状腺乳头状癌(PTC)患者体重指数(BMI)与临床病理特征之间的关系。
回顾性分析2016年5月至2017年3月我院收治的1579例PTC患者的临床资料。根据患者BMI不同,可分为体重过低组(BMI<18.5kg/m)、正常体重组(18.5≤BMI<24.0kg/m)、超重组(24.0≤BMI<28.0kg/m)和肥胖组(BMI≥28.0kg/m)。比较不同BMI组PTC患者的临床病理特征。
在本研究中,超重组甲状腺外侵犯(ETE)、T分期晚期(T III/IV)和肿瘤-淋巴结-转移分期晚期(TNM III/IV)的风险较高,相对于正常体重组,其比值比(OR)分别为1.99(1.41-2.81)、2.01(1.43-2.84)、2.94(1.42-6.07)。肥胖组ETE和T III/IV期的风险较高,相对于正常体重组,其OR分别为1.82(1.23-2.71)和1.82(1.23-2.70)。
BMI与PTC的侵袭性相关。超重组PTC患者发生ETE和TNM III/IV期的风险较高,肥胖组PTC患者发生ETE的风险较高。